Weight Watchers is Novo Nordisk's latest partnersip.

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a Strong Buy.

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Novo Nordisk (NVO) partners with WeightWatchers to expand access to Wegovy through NovoCare Pharmacy after ending a deal with Hims & Hers (HIMS). Read more here.

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss drug Wegovy. | Novo Nordisk is partnering with WeightWatchers to offer ...

Novo Nordisk A/S (NYSE:NVO) announced on June 26 that it will collaborate with WeightWatchers to begin distributing the bestselling weight-loss medication Wegovy, beginning July 1.